Corbus Pharmaceuticals I... (CRBP)
Company Description
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases.
It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases.
The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation.
It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings.
The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Country | United States |
IPO Date | Oct 27, 2014 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 28 |
CEO | Dr. Yuval Cohen Ph.D. |
Contact Details
Address: 500 River Ridge Drive Norwood, Massachusetts United States | |
Website | https://www.corbuspharma.com |
Stock Details
Ticker Symbol | CRBP |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001595097 |
CUSIP Number | 21833P103 |
ISIN Number | US21833P3010 |
Employer ID | 46-4348039 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Yuval Cohen Ph.D. | Chief Executive Officer & Director |
Dr. Ian Hodgson | Chief Operating Officer |
Christina Bertsch | Vice President of Human Resources |
Dr. Dominic Smethurst M.A., M.D. | Chief Medical Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 01, 2025 | ARS | Filing |
Apr 01, 2025 | DEFA14A | Filing |
Apr 01, 2025 | DEF 14A | Filing |
Mar 21, 2025 | 8-K | Current Report |
Mar 18, 2025 | 3 | Filing |
Mar 18, 2025 | 8-K | Current Report |
Mar 11, 2025 | 10-K | Annual Report |
Mar 11, 2025 | 8-K | Current Report |
Mar 07, 2025 | 4 | Filing |
Feb 18, 2025 | 4 | Filing |